Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A 1 chieve study
Aim: To explore the clinical safety and effectiveness of insulin detemir (IDet) in a subgroup of Indian patients with type 2 diabetes (T2D) switched from either insulin glargine (IGlar) or neutral protamine Hagedorn (NPH) insulin in the 24-week, non-interventional A 1 chieve study. Materials and Met...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2014-01-01
|
Series: | Indian Journal of Endocrinology and Metabolism |
Subjects: | |
Online Access: | http://www.ijem.in/article.asp?issn=2230-8210;year=2014;volume=18;issue=5;spage=715;epage=720;aulast=Wangnoo |
_version_ | 1819181472869777408 |
---|---|
author | Subhash Kumar Wangnoo Samit Ghosal Shahid Akhtar Raman Shetty Sudhir Tripathi |
author_facet | Subhash Kumar Wangnoo Samit Ghosal Shahid Akhtar Raman Shetty Sudhir Tripathi |
author_sort | Subhash Kumar Wangnoo |
collection | DOAJ |
description | Aim: To explore the clinical safety and effectiveness of insulin detemir (IDet) in a subgroup of Indian patients with type 2 diabetes (T2D) switched from either insulin glargine (IGlar) or neutral protamine Hagedorn (NPH) insulin in the 24-week, non-interventional A 1 chieve study. Materials and Methods : Indian patients with T2D switching from pre-study IGlaror NPH insulin to IDet were included. Safety and effectiveness outcomes were evaluated by the physicians in local clinical settings. Results : A total of 102 patients switched from IGlar to IDet (GLA group) and 39 patients switched from NPH insulin to IDet (NEU group). At baseline, the mean glycated hemoglobin A 1c (HbA 1c ) levels were 9.9 ± 1.8% in the GLA group and 9.1 ± 1.2% in the NEU group. No serious adverse drug reactions, serious adverse events, or major hypoglycemic events were reported in either group throughout the study. At baseline and Week 24, 11.8% and 7.5% of patients, respectively, reported overall hypoglycemic events in the GLA group. No hypoglycemic events were reported at Week 24 in the NEU group. At Week 24, the mean HbA 1c levels were 7.6 ± 0.9% in the GLA group and 7.3 ± 0.7% in the NEU group. The mean fasting plasma glucose, postprandial plasma glucose and quality of life also appeared to improve over 24 weeks. Conclusion: Switching to IDet therapy from IGlar and NPH insulin was well-tolerated and appeared to be associated with improved glycogenic control in Indian patients. |
first_indexed | 2024-12-22T22:30:47Z |
format | Article |
id | doaj.art-54c28355279b40dc88032ec5468e7998 |
institution | Directory Open Access Journal |
issn | 2230-8210 2230-9500 |
language | English |
last_indexed | 2024-12-22T22:30:47Z |
publishDate | 2014-01-01 |
publisher | Wolters Kluwer Medknow Publications |
record_format | Article |
series | Indian Journal of Endocrinology and Metabolism |
spelling | doaj.art-54c28355279b40dc88032ec5468e79982022-12-21T18:10:26ZengWolters Kluwer Medknow PublicationsIndian Journal of Endocrinology and Metabolism2230-82102230-95002014-01-0118571572010.4103/2230-8210.139239Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A 1 chieve studySubhash Kumar WangnooSamit GhosalShahid AkhtarRaman ShettySudhir TripathiAim: To explore the clinical safety and effectiveness of insulin detemir (IDet) in a subgroup of Indian patients with type 2 diabetes (T2D) switched from either insulin glargine (IGlar) or neutral protamine Hagedorn (NPH) insulin in the 24-week, non-interventional A 1 chieve study. Materials and Methods : Indian patients with T2D switching from pre-study IGlaror NPH insulin to IDet were included. Safety and effectiveness outcomes were evaluated by the physicians in local clinical settings. Results : A total of 102 patients switched from IGlar to IDet (GLA group) and 39 patients switched from NPH insulin to IDet (NEU group). At baseline, the mean glycated hemoglobin A 1c (HbA 1c ) levels were 9.9 ± 1.8% in the GLA group and 9.1 ± 1.2% in the NEU group. No serious adverse drug reactions, serious adverse events, or major hypoglycemic events were reported in either group throughout the study. At baseline and Week 24, 11.8% and 7.5% of patients, respectively, reported overall hypoglycemic events in the GLA group. No hypoglycemic events were reported at Week 24 in the NEU group. At Week 24, the mean HbA 1c levels were 7.6 ± 0.9% in the GLA group and 7.3 ± 0.7% in the NEU group. The mean fasting plasma glucose, postprandial plasma glucose and quality of life also appeared to improve over 24 weeks. Conclusion: Switching to IDet therapy from IGlar and NPH insulin was well-tolerated and appeared to be associated with improved glycogenic control in Indian patients.http://www.ijem.in/article.asp?issn=2230-8210;year=2014;volume=18;issue=5;spage=715;epage=720;aulast=WangnooGlargineIndiainsulin detemirneutral protamine Hagedorn insulintype 2 diabetes |
spellingShingle | Subhash Kumar Wangnoo Samit Ghosal Shahid Akhtar Raman Shetty Sudhir Tripathi Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A 1 chieve study Indian Journal of Endocrinology and Metabolism Glargine India insulin detemir neutral protamine Hagedorn insulin type 2 diabetes |
title | Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A 1 chieve study |
title_full | Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A 1 chieve study |
title_fullStr | Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A 1 chieve study |
title_full_unstemmed | Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A 1 chieve study |
title_short | Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A 1 chieve study |
title_sort | clinical experience of switching from glargine or neutral protamine hagedorn insulin to insulin detemir in type 2 diabetes observations from the indian cohort in the a 1 chieve study |
topic | Glargine India insulin detemir neutral protamine Hagedorn insulin type 2 diabetes |
url | http://www.ijem.in/article.asp?issn=2230-8210;year=2014;volume=18;issue=5;spage=715;epage=720;aulast=Wangnoo |
work_keys_str_mv | AT subhashkumarwangnoo clinicalexperienceofswitchingfromglargineorneutralprotaminehagedorninsulintoinsulindetemirintype2diabetesobservationsfromtheindiancohortinthea1chievestudy AT samitghosal clinicalexperienceofswitchingfromglargineorneutralprotaminehagedorninsulintoinsulindetemirintype2diabetesobservationsfromtheindiancohortinthea1chievestudy AT shahidakhtar clinicalexperienceofswitchingfromglargineorneutralprotaminehagedorninsulintoinsulindetemirintype2diabetesobservationsfromtheindiancohortinthea1chievestudy AT ramanshetty clinicalexperienceofswitchingfromglargineorneutralprotaminehagedorninsulintoinsulindetemirintype2diabetesobservationsfromtheindiancohortinthea1chievestudy AT sudhirtripathi clinicalexperienceofswitchingfromglargineorneutralprotaminehagedorninsulintoinsulindetemirintype2diabetesobservationsfromtheindiancohortinthea1chievestudy |